GLP1R and inflammatory bowel disease: To address this gap, we conducted a systematic review and meta-analysis to critically evaluate whether GLP-1 receptor agonists are associated with improved clinical outcomes in patients particularly those with metabolic comorbidities, with a specific focus on two key endpoints: IBD-related surgery and IBD-related complications.